In the last few years, CD19-targeting chimeric antigen receptor (CAR) T cell therapy showed high rates of complete remission in B cell acute lymphoblastic leukemia (B-ALL), and moderate response rates in both diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia [1–3]. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.